STAT5B and lung carcinoma: Here, we identified the activity of the ‘IL2 signaling events mediated by STAT5’ pathway (Fig. 2a) as a robust biomarker for the response to two highly similar Bcl-2 protein–family inhibitors (ABT-263 and ABT-737) in lung cancer cell lines.